AI in Healthcare: Benefits & Risks in Pakistan
Pakistan has one physician for every 1,491 people. Radiologists are concentrated in major urban centres, leaving vast rural populations without access to diagnostic imaging. Chronic diseases including diabetes, heart disease, and tuberculosis represent an enormous and growing burden on a health system that is chronically under-resourced. Into this context, artificial intelligence is arriving with specific, documented capabilities — and with risks that are equally specific and documented. The question for Pakistan is not whether AI in healthcare matters. It is whether the country can deploy it in a way that closes gaps rather than widening them.
Key Takeaways
- The global AI in healthcare market is projected to reach $52.28 billion in 2026, with 1,451 FDA-authorised AI-enabled medical devices — 1,104 of them in radiology.
- In Pakistan, 72.5% of healthcare professionals demonstrate good knowledge of AI, but clinical adoption remains concentrated in radiology at 60.1%.
- AI-generated medical reports achieve 87.3% overall accuracy — significantly outperforming surgeon-written reports at 72.8%, with fewer discrepancies and lower rates of clinically significant errors.
- 80% of routine customer interactions in healthcare will be fully handled by AI by 2029, according to Gartner’s March 2025 research.
- The benefits are real, documented, and significant. So are the risks: algorithmic bias, accountability gaps, and deployment without governance frameworks are the primary failure modes.
What Is AI in Healthcare?
AI in healthcare refers to the application of artificial intelligence — including machine learning, deep learning, natural language processing, and computer vision — to clinical, administrative, and research functions across the health system. It encompasses algorithms that detect tumours in medical images, systems that process and summarise electronic health records, machine learning models that identify drug candidates, and chatbots that handle patient scheduling and triage.
The breadth of AI applications in healthcare is wider than most people realise, and the maturity of those applications varies significantly. AI in radiology and medical imaging has FDA clearance and peer-reviewed evidence supporting active clinical deployment. AI in electronic health records is reducing documentation time measurably. AI in drug discovery is compressing timelines that once took decades. AI in clinical decision support is advancing rapidly. Each application sits at a different stage of maturity, carries a different evidence base, and demands a different governance framework.
AI in Healthcare in Pakistan — Where We Are
Pakistan’s AI healthcare landscape is defined by a significant gap between healthcare professionals’ knowledge of AI and its actual clinical deployment. A 2026 cross-sectional study published in Health Science Reports covering healthcare professionals in Balochistan found that 72.5% of participants demonstrated good knowledge of AI. However, AI adoption in clinical settings was concentrated in radiology at 60.1% — suggesting that deployment beyond imaging has not yet reached most clinical settings.
A 2024 study published in BMC Health Services Research examining attitudes and readiness among medical and dental practitioners across Pakistani hospitals found that while practitioners demonstrated awareness of AI’s potential, significant concerns remained around integration into practice, data privacy, and the adequacy of training. Readiness — structural, infrastructural, and human — remains the binding constraint.
The structural challenges are real: inconsistent electricity supply complicates high-performance computing deployments, rural broadband penetration limits the reach of cloud-based AI tools, and the absence of standardised electronic health record systems across most public sector hospitals means the data infrastructure that AI requires simply does not yet exist in most settings.
Pakistan’s National AI Policy 2025 specifically identifies healthcare as a priority sector for AI transformation, with sector-specific roadmaps beginning rollout in 2025–2026. The policy intent is in place. The implementation infrastructure — trained clinicians, governance frameworks, data systems, and structured AI deployment protocols — is what needs to be built alongside it. skr1pt’s analysis of the National AI Policy covers what that policy means for organisations across sectors, including healthcare.
The Benefits of AI in Healthcare
Medical Imaging and Diagnostics
Radiology dominates AI healthcare deployment globally for a clear reason: the evidence is strongest here. According to SQ Magazine’s 2026 healthcare AI statistics, 1,104 of the FDA’s 1,451 authorised AI medical devices are in radiology — 76.1% of all authorised devices. Around 73% of physicians now use AI for diagnostic imaging, making it the single most common clinical AI application.
The clinical results are specific. A large trial of AI for diabetic retinopathy screening reported sensitivity of 99.2% and specificity of 97.6%, enabling near-real-time diagnosis from retinal images — often without the need for pupil dilation. An AI-based screening system delivered conclusive reports for over 97% of eyes examined. In chest radiography, AI used as a second reader improved radiologist sensitivity by approximately 10 percentage points with only minimal loss in specificity.
For Pakistan, where the specialist radiologist-to-patient ratio is severely stretched and diagnostic imaging capacity in district and tehsil hospitals is limited or absent, these results carry direct structural implications. AI-assisted diagnostic imaging deployed in under-resourced settings could extend specialist-level diagnostic capacity to populations that currently have no realistic access to it — not as a long-term aspiration, but as a near-term deployable capability.
Clinical Documentation and Electronic Health Records
Administrative burden is one of the most acute problems in healthcare globally — and one of the most immediately addressable through AI. A large JAMA study found AI scribes cut total electronic health record time by 13.4 minutes and documentation time by 16.0 minutes per clinical encounter on average. Meta-analytic evidence shows generative AI-based systems reduce documentation time by approximately 40%, while voice-recognition AI scribing cuts charting time by 28.8%.
The quality finding is equally significant. According to SQ Magazine’s compilation of clinical data, AI-generated medical reports achieve 87.3% overall accuracy — compared to surgeon-written reports at 72.8%. Only 29.1% of AI-generated reports contained one or more discrepancies, versus 53.2% of surgeon-written reports. Clinically significant discrepancies appeared in just 12.7% of AI-generated reports, compared to 27.2% for surgeon-written reports.
For Pakistan’s public health system, where physician workload is among the highest in the region and patient volumes are enormous, these are not marginal efficiency gains. They are structural interventions — time freed from documentation is time that can return to patient interaction.
Drug Discovery and Clinical Trials
AI is compressing one of medicine’s most expensive and time-consuming processes. A 2026 peer-reviewed study published in PubMed synthesising evidence from 2021 to 2025 found AI demonstrated prediction accuracies of 86–98% in drug discovery, and an 80% improvement in clinical trial recruitment efficiency. AI-enabled workflows have reduced the time and cost to bring a new molecule to the preclinical candidate stage by up to 40% in time and 30% in costs for complex targets.
According to SQ Magazine’s drug discovery statistics, global pipelines now include over 3,000 drug candidates discovered or repurposed with AI assistance. The AI-enabled drug discovery market is projected to reach $33.95 billion by 2036 at a 15.3% CAGR. AI has compressed some development timelines from over 10 years to roughly 3–6 years for selected programmes.
For Pakistan’s pharmaceutical sector and medical research institutions — particularly those contributing to neglected tropical diseases prevalent in the region — the ability to participate in and benefit from AI-enabled drug discovery platforms represents a meaningful and underexplored opportunity.
Predictive Analytics and Patient Outcomes
According to healthcare AI statistics compiled by SQ Magazine, hospitals using AI predictive analytics report 10–20% reductions in 30-day readmission rates for high-risk patients. Sepsis-focused AI algorithms have achieved 70–85% accuracy in early detection, outperforming traditional scoring tools. One AI sepsis prediction system produced a 22.7% reduction in 30-day readmissions, a 32.3% drop in length of stay, and a 39.5% reduction in in-hospital mortality — outcomes that represent direct, measurable improvements in patient care and resource allocation.
In Pakistan, where sepsis and preventable complications from chronic diseases drive a disproportionate share of hospital mortality, these are not abstract statistics. They represent lives that could be saved with tools that already exist and are already deployed in other health systems.
Patient Engagement and Virtual Health Assistants
About 52% of healthcare providers now use AI chatbots for scheduling, triage, and patient education. Over 70% of patients report being satisfied with their interactions with AI virtual assistants in clinical and administrative use cases. SQ Magazine’s analysis of mental health chatbot trials found AI conversational agents significantly reduce symptoms of depression, with effect sizes of 0.64 for depression and 0.70 for psychological distress.
For Pakistan, where mental health services are severely under-resourced and stigma around seeking help remains a significant barrier, AI-powered mental health support tools — appropriately governed and culturally contextualised — represent an access intervention rather than a convenience feature.
The Risks of AI in Healthcare
The benefits above are real. They come with risks that are equally documented and must be addressed with equal seriousness.
Algorithmic Bias
AI models learn from the data they are trained on. If that data overrepresents certain populations — wealthier patients, urban patients, patients from specific ethnic groups — the model’s performance on underrepresented populations will be weaker, sometimes dangerously so. Under the EU AI Act, which entered full effect for most high-risk health AI systems on 2 August 2026, AI used in medical devices is classified as high-risk and requires documented dataset governance, including evidence of representativeness.
For Pakistan, this risk is acute. AI diagnostic systems trained primarily on datasets from high-income countries may perform differently — and potentially less reliably — on Pakistani patient populations whose disease presentations, comorbidities, and imaging characteristics may differ. Deploying AI diagnostic tools without validating their performance on local populations is a governance failure, not merely a technical limitation.
Accountability and Human Oversight
When an AI system contributes to a diagnostic error, the question of accountability is not straightforward — and in most jurisdictions, including Pakistan, the legal and ethical frameworks to address it are not yet fully developed. Healthcare guidance cited by SQ Magazine stresses that high-risk AI must include built-in human oversight by design — not as an afterthought. Regulators increasingly expect documented risk assessments, dataset governance, incident response plans, and lifecycle model monitoring.
The human-in-the-loop principle is not optional in healthcare AI. It is the line between AI that augments clinical judgment and AI that bypasses it.
Data Privacy and Security
AI in healthcare requires large volumes of patient data — and Pakistan’s data protection framework, while improving, is not yet mature. The absence of a fully enacted and enforced personal data protection law creates governance ambiguity around how patient data used to train or operate AI systems should be handled, stored, consented to, and protected.
Healthcare organisations in Pakistan that are evaluating AI deployments need governance frameworks in place before deployment — not after. skr1pt’s AI governance consulting work addresses exactly this gap, helping organisations build the policy and accountability infrastructure that responsible AI adoption requires.
The Deployment Without Readiness Problem
A 2026 industry analysis on Uvik found that while around 80% of hospitals globally report using AI in at least one clinical or operational function, fewer than 20% report sustained high-success use of AI in core clinical diagnosis. The gap between nominal adoption and effective deployment is the defining challenge in healthcare AI globally — and it is a challenge Pakistan can learn from rather than repeat.
Deploying AI tools in healthcare without the clinical training, governance frameworks, data quality, and human oversight structures to support them does not accelerate care quality. It creates the risk of confident, fast, wrong outputs reaching clinical decisions.
The Future of AI in Healthcare in Pakistan
The future of AI in Pakistan’s healthcare system will be shaped by the choices made in the next two to three years about how, where, and with what governance AI is deployed. The technology is accessible and increasingly affordable. The structural constraints — data infrastructure, electricity reliability, trained professionals, and governance frameworks — are what determine whether AI becomes a health equity intervention or a feature of private urban healthcare inaccessible to the majority.
Three priorities stand out for Pakistan specifically: investing in standardised electronic health records across public sector hospitals, which is the data foundation on which all healthcare AI depends; training clinicians not just in how AI tools work but in how to oversee and govern them; and validating AI diagnostic tools on Pakistani patient populations before deploying them at scale.
The direction of travel is encouraging. The National AI Policy 2025 is a serious document. The growing body of Pakistani research on AI adoption in healthcare is building the evidence base. And the availability of high-impact, low-infrastructure-requirement AI applications — particularly in diagnostic imaging and clinical documentation — means meaningful deployment can begin now, in parallel with longer-term infrastructure investment.
